Drug intelligence / Profile preview

EK-004

Development stage: Preclinical
Lead developer: Shanghai Enkai Cell Technology
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

EK-004 is a chimeric antigen receptor T-cell (CAR-T) therapy targeting Glypican-3 (GPC3), currently in preclinical development by Shanghai Enkai Cell Technology (Shanghai NK Cell Technology). GPC3 is a cell-surface oncofetal protein that is highly expressed in hepatocellular carcinoma (HCC) but has limited expression in normal adult tissues, making it an ideal target for immunotherapy. EK-004 is designed to recognize and eliminate GPC3-positive tumor cells, specifically for the treatment of liver cancer.

Targets

GPC3 (Glypican-3)

Beyond the preview

Go deeper on EK-004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EK-004.

Explore the full profile